Literature DB >> 9062110

Crystal structure of a prolonged-acting insulin with albumin-binding properties.

J L Whittingham1, S Havelund, I Jonassen.   

Abstract

The fatty acid acylated insulin, Lys(B29)-tetradecanoyl, des-(B30) human insulin, has been crystallized and the structure determined by X-ray crystallography. The fatty acid substituent on residue B29 Lys binds reversibly to circulating albumin protein in vivo, and by this mechanism the hormone's action is prolonged. Crystals of the fatty acid insulin grow in space group R3, with two dimers in the asymmetric unit, and diffract to 1.8 A spacing. The structure has been solved by molecular replacement and refined using a maximum likelihood method. The crystal structure consists of R6 zinc insulin hexamers which contain phenol. The fatty acids can be seen bound between the hexamers, making specific interactions with the side chains of residue B1 Phe; however, the lysine side chains to which the fatty acids are covalently attached are mostly disordered. The mode of binding of the fatty acids appears to be determined by crystal packing, and whether or not they interact with the protein in this way in solution remains uncertain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062110     DOI: 10.1021/bi9625105

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  NB1-C16-insulin: site-specific synthesis, purification, and biological activity.

Authors:  H Mei; C Yu; K K Chan
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

2.  Normal modes for predicting protein motions: a comprehensive database assessment and associated Web tool.

Authors:  Vadim Alexandrov; Ursula Lehnert; Nathaniel Echols; Duncan Milburn; Donald Engelman; Mark Gerstein
Journal:  Protein Sci       Date:  2005-03       Impact factor: 6.725

3.  Influence of acylation on the adsorption of insulin to hydrophobic surfaces.

Authors:  Charlotte Pinholt; Susanne Hostrup; Jens Thostrup Bukrinsky; Sven Frokjaer; Lene Jorgensen
Journal:  Pharm Res       Date:  2010-12-29       Impact factor: 4.200

Review 4.  Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus.

Authors:  Harriet L Miles; Carlo L Acerini
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 5.  Controlled release of biologics for the treatment of type 2 diabetes.

Authors:  Caslin A Gilroy; Kelli M Luginbuhl; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2015-12-02       Impact factor: 9.776

Review 6.  The role of insulin detemir in overweight type 2 diabetes management.

Authors:  Yared N Demssie; Naveed Younis; Handrean Soran
Journal:  Vasc Health Risk Manag       Date:  2009-06-29

7.  The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.

Authors:  Svend Havelund; Anne Plum; Ulla Ribel; Ib Jonassen; Aage Vølund; Jan Markussen; Peter Kurtzhals
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

8.  Incorporating a generic model of subcutaneous insulin absorption into the AIDA v4 diabetes simulator. 3. Early plasma insulin determinations.

Authors:  Eldon D Lehmann; Cristina Tarín; Jorge Bondia; Edgar Teufel; Tibor Deutsch
Journal:  J Diabetes Sci Technol       Date:  2009-01

Review 9.  Insulin detemir: a review of its use in the management of diabetes mellitus.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

10.  Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide.

Authors:  Angélique Gajahi Soudahome; Aurélie Catan; Pierre Giraud; Sandrine Assouan Kouao; Alexis Guerin-Dubourg; Xavier Debussche; Nathalie Le Moullec; Emmanuel Bourdon; Susana B Bravo; Beatriz Paradela-Dobarro; Ezequiel Álvarez; Olivier Meilhac; Philippe Rondeau; Joël Couprie
Journal:  J Biol Chem       Date:  2018-02-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.